CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT

Expected improvements in survival did not emerge from a large analysis of data comparing selective internal radiotherapy (SIRT) plus chemotherapy to chemotherapy, but an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer (mCRC), according to findings from the SIRFLOX trial presented at the 2017 World Congress on Gastrointestinal Cancer.¹
... to read the full story